Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of Voxzogo in children with achondroplasia
jRCT2080224830Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, open-label trial of vosoritide in achondroplasia (ACH) (2 arms), sponsored by BioMarin Pharmaceutical Inc. Started Aug 2019; status: completed.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2080224830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224830.